Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
doi: 10.1007/BF00399926
Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells
Hidden dangers Even though the early results seem exciting, these experimental compounds can be dangerous
They do not present any known health risks
Intestinal Metaplasia in the Esophageal Remnant Is Rare After Ivor Lewis Esophagectomy
US$ 23.91
US$ 21.73
US$ 21.64
US$ 24.64
US$ 28.65
US$ 21.42
US$ 10595.00
Sold : Login>>
